Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature …

M Buglione, R Cavagnini, F Di Rosario… - Critical reviews in …, 2016 - Elsevier
Radiotherapy alone or in combination with chemotherapy and/or surgery is the typical
treatment for head and neck cancer patients. Acute side effects (such as oral mucositis …

Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and …

M Buglione, R Cavagnini, F Di Rosario… - Critical reviews in …, 2016 - Elsevier
Radiotherapy alone or in combination with chemotherapy and/or surgery is a well-known
radical treatment for head and neck cancer patients. Nevertheless acute side effects (such …

[HTML][HTML] A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients

AE Guerini, S Pedretti, E Salah, EL Simoncini… - Scientific Reports, 2020 - nature.com
Abstract Cyclin dependent kinases 4/6 (CDK4/6) inhibitors gained an essential role in the
treatment of metastatic breast cancer. Nevertheless, data regarding their use in combination …

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

V Ferrari, F Valcamonico, V Amoroso… - Cancer chemotherapy …, 2006 - Springer
Introduction: Single agent gemcitabine (GEM) is the standard treatment of pancreatic
adenocarcinoma. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. Recent …

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fifth symposium on primary systemic therapy in …

V Amoroso, D Generali, T Buchholz… - Journal of the …, 2015 - academic.oup.com
Expert consensus-based recommendations regarding key issues in the use of primary (or
neoadjuvant) systemic treatment (PST) in patients with early breast cancer are a valuable …

[HTML][HTML] PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

F Cognetti, R Masetti, A Fabi, G Bianchi, D Santini… - NPJ Breast …, 2021 - nature.com
Clinicopathological prognostic features have limited value to identify with precision newly
diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer …

[HTML][HTML] Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy

R Pedersini, P di Mauro, S Bosio, B Zanini, A Zanini… - Scientific Reports, 2021 - nature.com
Change in eating habits in early breast cancer (EBC) patients during chemotherapy has
been poorly studied in the literature. The primary aim of this study was to prospectively …

Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study

R Pedersini, S Monteverdi, G Mazziotti, V Amoroso… - Bone, 2017 - Elsevier
Background The impact of long-term adjuvant therapy with aromatase inhibitors (AIs) on
vertebral fracture (VF) risk is still unclear. Objective In this cross-sectional study, we explored …

Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy

R Pedersini, V Amoroso, F Maffezzoni… - JAMA Network …, 2019 - jamanetwork.com
Importance Aromatase inhibitors induce a profound depletion in serum estrogen levels.
Postmenopausal obese women receiving aromatase inhibitor therapy may be at increased …

The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase …

S Monteverdi, R Pedersini, F Gallo… - Journal of Bone and …, 2021 - academic.oup.com
Aromatase inhibitors (AIs) induce depletion of estrogen levels, causing bone loss and
increased fracture risk in women with breast cancer. High fat body mass (FBM) emerged as …